Livzon Pharmaceutical Group Inc Class H (DE:LP6)
FRANKFURT:LP6
LP6 Stock Chart & Stats
€3.48
€0.00(0.00%)
At close: 4:00 PM EST
€3.48
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.76 - €4.30
Previous CloseN/A
Volume0.00
Average Volume (3M)137.00
Market Cap
€3.16B
Enterprise Value€22.27B
Total Cash (Recent Filing)€9.56B
Total Debt (Recent Filing)€2.89B
Price to Earnings (P/E)13.7
Beta0.28
Next Earnings
Aug 20, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.20
Shares Outstanding299,807,130
10 Day Avg. Volume338
30 Day Avg. Volume137
Financial Highlights & Ratios
PEG Ratio-8.67
Price to Book (P/B)1.65
Price to Sales (P/S)1.97
P/FCF Ratio9.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.28Price Target Upside22.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.26
Revenue Forecast (FY)€1.34B
Bulls Say, Bears Say
Bulls Say
Profitability MarginsHigh and consistent gross, EBIT and net margins (~65%, ~22%, ~17%) indicate durable pricing power and efficient manufacturing. Over 2–6 months this supports steady cash earnings, resilience versus pricing pressure in generics/specialty pharma, and a reliable earnings base for reinvestment.
Conservative LeverageLow debt-to-equity (~0.27) and a sizeable equity base provide balance-sheet flexibility and lower refinancing risk. This conservative capital structure supports continued dividends, R&D or selective M&A without materially raising leverage, improving resilience across industry cycles.
Free Cash Flow StrengthGrowing free cash flow (~5.5% TTM) and FCF near 0.82x of net income show solid cash generation and earnings quality. Persistent FCF supports shareholder distributions, organic R&D spend and working-capital needs, enhancing long-term financial flexibility and strategic optionality.
Bears Say
Revenue DeclineA multi-year top-line decline (TTM -2.8%) signals weakening demand, pricing pressure or share loss. Sustained revenue contraction limits scale benefits, constrains reinvestment capacity and makes it harder to offset fixed costs, risking margin erosion and slower long-term growth absent a clear recovery.
Weak Cash Conversion Vs EBITOCF covers only ~44% of EBIT, implying that reported operating profits are not consistently converting to cash due to working-capital or timing issues. This raises free-cash-flow volatility risk and may constrain steady dividend funding or capex when working-capital needs rise.
Limited Balance-sheet CatalystsA stable asset base coupled with slowing growth suggests few balance-sheet levers to accelerate expansion organically. Without new product, regulatory or commercial catalysts, returns on capital may stagnate and the company could lack near-term drivers to re-accelerate revenue.
Livzon Pharmaceutical Group News
LP6 FAQ
What was Livzon Pharmaceutical Group Inc Class H’s price range in the past 12 months?
Livzon Pharmaceutical Group Inc Class H lowest stock price was €2.76 and its highest was €4.30 in the past 12 months.
What is Livzon Pharmaceutical Group Inc Class H’s market cap?
Livzon Pharmaceutical Group Inc Class H’s market cap is €3.16B.
When is Livzon Pharmaceutical Group Inc Class H’s upcoming earnings report date?
Livzon Pharmaceutical Group Inc Class H’s upcoming earnings report date is Aug 20, 2026 which is in 76 days.
How were Livzon Pharmaceutical Group Inc Class H’s earnings last quarter?
Livzon Pharmaceutical Group Inc Class H released its earnings results on Apr 23, 2026. The company reported €0.083 earnings per share for the quarter, missing the consensus estimate of €0.092 by -€0.009.
Is Livzon Pharmaceutical Group Inc Class H overvalued?
According to Wall Street analysts Livzon Pharmaceutical Group Inc Class H’s price is currently Undervalued.
Does Livzon Pharmaceutical Group Inc Class H pay dividends?
Livzon Pharmaceutical Group Inc Class H does not currently pay dividends.
What is Livzon Pharmaceutical Group Inc Class H’s EPS estimate?
Livzon Pharmaceutical Group Inc Class H’s EPS estimate is 0.08.
How many shares outstanding does Livzon Pharmaceutical Group Inc Class H have?
Livzon Pharmaceutical Group Inc Class H has 299,807,130 shares outstanding.
What happened to Livzon Pharmaceutical Group Inc Class H’s price movement after its last earnings report?
Livzon Pharmaceutical Group Inc Class H reported an EPS of €0.083 in its last earnings report, missing expectations of €0.092. Following the earnings report the stock price went up 1.379%.
Which hedge fund is a major shareholder of Livzon Pharmaceutical Group Inc Class H?
Currently, no hedge funds are holding shares in DE:LP6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Livzon Pharmaceutical Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.08%
12-Months-Change
Fundamentals
Return on Equity
13.95%
Trailing 12-Months
Asset Growth
3.72%
Trailing 12-Months
Company Description
Livzon Pharmaceutical Group Inc Class H
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.
LP6 Stock 12 Month Forecast
Average Price Target
€4.28
▲(22.91% Upside)
Technical Analysis
The United Laboratories International Holdings
―
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
China Resources Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---